Rhumbline Advisers purchased a new position in Progyny Inc (NASDAQ:PGNY) during the fourth quarter, Holdings Channel.com reports. The firm purchased 10,620 shares of the company’s stock, valued at approximately $292,000.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Victory Capital Management Inc. acquired a new stake in Progyny during the 4th quarter worth about $50,000. Strs Ohio purchased a new stake in Progyny during the fourth quarter valued at about $82,000. New York State Common Retirement Fund purchased a new stake in Progyny during the fourth quarter valued at about $285,000. Sigma Planning Corp acquired a new position in shares of Progyny in the fourth quarter worth about $342,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of Progyny in the fourth quarter worth about $1,118,000. 35.45% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have recently weighed in on PGNY shares. Goldman Sachs Group started coverage on shares of Progyny in a research report on Tuesday, November 19th. They issued a “buy” rating and a $33.00 target price on the stock. SVB Leerink began coverage on shares of Progyny in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $28.00 price target for the company. JPMorgan Chase & Co. assumed coverage on shares of Progyny in a research note on Wednesday, November 27th. They issued an “overweight” rating and a $26.00 price objective for the company. Citigroup assumed coverage on shares of Progyny in a research report on Wednesday, November 27th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Piper Jaffray Companies started coverage on shares of Progyny in a research report on Wednesday, November 27th. They set an “overweight” rating and a $33.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $30.00.
Progyny stock traded down $1.91 during mid-day trading on Monday, hitting $23.31. The company’s stock had a trading volume of 15,557 shares, compared to its average volume of 600,473. Progyny Inc has a 52-week low of $13.29 and a 52-week high of $36.50. The firm has a market cap of $2.31 billion and a P/E ratio of 213.23. The stock’s 50 day moving average is $30.10.
Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, March 5th. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.01). The firm had revenue of $65.10 million during the quarter, compared to the consensus estimate of $66.07 million. The business’s quarterly revenue was up 122.9% on a year-over-year basis. As a group, analysts predict that Progyny Inc will post 0.32 earnings per share for the current year.
Progyny Company Profile
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
See Also: What is the Consumer Price Index (CPI)?
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny Inc (NASDAQ:PGNY).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.